Results 151 to 160 of about 2,682 (215)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
The ‘Slow Burn’ Phenotype: How Relative Caloric Intake Reveals Hidden Cardiovascular Risk Beyond BMI
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective Body mass index (BMI) inadequately captures heterogeneity in cardiovascular (CV) risk. We hypothesised that a ‘Slow Burn’ phenotype, defined as lower‐than‐expected energy intake relative to BMI, age, and sex, identifies individuals at elevated CV risk across the BMI spectrum.
Yongin Cho +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González +14 more
wiley +1 more source
SGLT2 independent effects of the SGLT2 inhibitor empagliflozin
This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder +13 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit
Diabetes, Obesity and Metabolism, EarlyView.
Salvatore Corrao +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function.
Maria Novella Nicese +13 more
wiley +1 more source